 CAMBRIDGE, Mass., June 21, 2021 GLOBE NEWSWIRE -- Agios Pharmaceuticals, Inc. NASDAQ: AGIO, a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted a New Drug Application NDA for mitapivat to the U.S. Food and Drug Administration FDA for the treatment of adults with pyruvate kinase PK deficiency. 